Albumin (as Excipient) Market to Reach US$ 1200 Mn by 2026

Global Albumin (as Excipient) Market – Snapshots

Albumin is a water soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions.

View Report-
https://www.transparencymarketresearch.com/albumin-market.html

Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries. However, usage of albumin as multifunctional excipient is increasing due to rise in consumption for applications such as drug formulation, vaccines, drug discovery, culture medium, stabilizing agent, and diagnostics.

The global albumin (as excipient) market was valued at US$ 750 Mn in 2017 and is anticipated to reach US$ 1200 Mn by 2026 at a CAGR of over 5.0% from 2018 to 2026. Grant of regulatory approvals and trials coupled with subsequent launch of albumin-based products is expected to boost the growth of the market during the forecast period. For instance, in May 2017, China’s Food and Drug Administration granted approval to clinical trials of human blood albumin produced from transgenic rice seeds.

Request A Sample-
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3984

Increase in usage of albumin as multifunctional excipient, shift toward usage of recombinant albumin, and grant of regulatory approvals are the key factors driving the market. However, high cost and expertise required to set up production plants and stringent regulatory criteria restrain the market. Emerging markets such as India, China, Brazil, and South Africa present significant opportunities in the albumin as an excipient market owing to growing contract research manufacturing.

Moreover, technological developments in drug formulation & drug delivery and increase in access to technologies such as use of albumin in cell culture media present lucrative opportunities for investors. Hence, investments by manufacturers in these developing markets, increase in contract research manufacturing, and rise in demand and awareness among the end-users are expected to boost the growth of the albumin as an excipient market.

The global albumin (as excipient) market has been segmented based on product, application, end-user, and region. In terms of product, the human serum albumin segment is anticipated to account for major market share of 80% in terms of revenue during the forecast period. Growth of the segment is attributed to increase in prevalence of life-threatening disorders and conditions, especially liver diseases, infections, and cardiac surgeries leading to hypoalbuminemia.

Other factors driving the segment include rise in adoption of albumin products and increase in usage for non-therapeutic applications across the world. Based on application, drug delivery is expected to be the most attractive segment during the forecast period. Collaboration between pharmaceutical and biotechnology companies for the use of recombinant albumin-based drug delivery systems is likely to boost the growth of the segment. In terms of end-user, the pharmaceutical & biotechnology industry segment is expected to dominate the market from 2018 to 2026. The segment was valued at US$ 500 Mn in 2017. Rise in research and developmental activities for the development of technologically advanced products and increase in government funding are attributed to the growth of the segment.

Request For Custom Research-
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3984

Geographically, North America and Europe are projected to be highly attractive markets for albumin as excipient during the forecast period. Rise in investments in life sciences by a large number of biopharmaceutical companies and research institutes is expected to boost the market in the regions during the forecast period.

Demand for albumin is high in countries such as India and China. However, uptake of these therapeutics is low due to lack of awareness about these products and their therapeutic uses. Hence, awareness programs conducted by organizations such as PPTA, which include International Plasma Awareness Week, to help increase awareness about plasma donation and the different plasma protein therapies available along with their potential uses are expected to increase the uptake of these therapeutics in treating various conditions.

Major players in the global albumin (as excipient) market are Albumedix A/S (Novozyme A/S), Albumin Therapeutics, LLC, Biotest AG, CSL Behring LLC, Grifols International, S.A., HiMedia Laboratories Pvt. Ltd., InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, and Sigma-Aldrich Co. (Merck KGaA). The companies are focusing on partnering with leading pharmaceutical companies to boost the research and development activities in order to develop technologically advanced albumin products.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website:www.transparencymarketresearch.com

This release was published on openPR.